Aavogen

Aavogen is a preclinical-stage biotechnology company focused on developing transformative gene therapies for muscle-wasting diseases. Founded by the discoverers of myostatin, the company leverages a proprietary adeno-associated virus (AAV) platform to deliver potent inhibitors of the myostatin/activin signaling pathway. Their lead programs target conditions such as sarcopenia, cancer cachexia, and Duchenne muscular dystrophy by promoting muscle growth and improving physical function. Aavogen's approach aims to provide long-term therapeutic benefits through a single administration, addressing significant unmet needs in aging and chronic illness. The company operates out of Farmington, Connecticut, maintaining strong ties to academic research institutions.